Exploring the Role of Ceramides by Elisa Analysis: Orchestrating the Pathogenesis of Diabetes Mellitus and its Complications

Download Article

DOI: 10.21522/TIJPH.2013.12.03.Art066

Authors : Parameswari. R. P, Lakshmi Thangavelu, Ashita Dilip, Akash R

Abstract:

The roles of adiponectin and ceramides, crucial molecules with differing impacts on the advancement of type 2 diabetes (T2D), are intricate and not entirely comprehended. It's important to highlight those ongoing investigations are essential to completely comprehend how they contribute to the development and progression of T2D. Therefore, the present study aimed to assess the role of ceramides and adiponectin in Type 2 diabetic conditions. The study included 20 patients with type 2 diabetes mellitus and 20 normal subjects. The study included healthy age-matched individuals as controls. Blood samples were collected from all the subjects and the concentration of Ceramides and adiponectin in plasma was determined by ELISA analysis. The results of the present study demonstrated considerably higher concentrations of Ceramides in type 2 diabetes patients in comparison to that of the healthy aged-matched control group. The adiponectin levels were found to be significantly (p<0.05) decreased in the T2D group than that of the normal healthy control group. The analysis showed that the markers, ceramides as well and adiponectin were significantly altered in type 2 diabetic conditions indicating an imbalance between these two molecules can significantly influence the development and progression of type 2 diabetes.

References:

[1]. Mandal, N., Grambergs, R., Mondal, K., Basu, S.K., Tahia, F. and Dagogo-Jack, S., 2021. Role of ceramides in the pathogenesis of diabetes mellitus and its complications. Journal of Diabetes and its Complications, 35(2), p.107734.
[2]. Brownlee, M., 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54(6), pp.1615-1625.
[3]. Pickup, J.C. and Crook, M.A., 1998. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia, 41, pp.1241-1248.
[4]. Chaurasia, B. and Summers, S.A., 2015. Ceramides–lipotoxic inducers of metabolic disorders. Trends in Endocrinology & Metabolism, 26(10), pp.538-550.
[5]. Al-Said, N.H., Taha, F.M., Abdel-Aziz, G.M. and Abdel-Tawab, M.S., 2018. Fetuin-A level in type 2 diabetic patients: relation to microvascular complications. The Egyptian Journal of Internal Medicine, 30, pp.121-130.
[6]. Sokolowska, E. and Blachnio-Zabielska, A., 2019. The role of ceramides in insulin resistance. Frontiers in Endocrinology, 10, p.436871.
[7]. Galadari, S., Rahman, A., Pallichankandy, S., Galadari, A. and Thayyullathil, F., 2013. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids in health and disease, 12, pp.1-16.
[8]. Achari, A.E. and Jain, S.K., 2017. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. International journal of molecular sciences, 18(6), p.1321.
[9]. Holland, W.L., Adams, A.C., Brozinick, J.T., Bui, H.H., Miyauchi, Y., Kusminski, C.M., Bauer, S.M., Wade, M., Singhal, E., Cheng, C.C. and Volk, K., 2013. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell metabolism, 17(5), pp.790-797.
[10]. ElSayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., Collins, B.S., Cusi, K., Das, S.R., Gibbons, C.H. and Giurini, J.M., 2023. Introduction and methodology: standards of care in diabetes—2023. Diabetes Care, 46(Supplement_1), pp.S1-S4.
[11]. Stern, J.H., Rutkowski, J.M. and Scherer, P.E., 2016. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell metabolism, 23(5), pp.770-784.
[12]. Al-Mhanna, S.B., Batrakoulis, A., Mohamed, M., Alkhamees, N.H., Sheeha, B.B., Ibrahim, Z.M., Aldayel, A., Muhamad, A.S., Rahman, S.A., Afolabi, H.A. and Zulkifli, M.M., 2024. Home-based circuit training improves blood lipid profile, liver function, musculoskeletal fitness, and health-related quality of life in overweight/obese older adult patients with knee osteoarthritis and type 2 diabetes: a randomized controlled trial during the COVID-19 pandemic. BMC Sports Science, Medicine and Rehabilitation, 16(1), p.125.
[13]. Borodzicz, S., Czarzasta, K., Kuch, M. and Cudnoch-Jedrzejewska, A., 2015. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids in health and disease, 14, pp.1-8.
[14]. Summers, S.A., 2018. Could ceramides become the new cholesterol?. Cell metabolism, 27(2), pp.276-280.
[15]. Goetz, R., 2013. Adiponectin—a mediator of specific metabolic actions of FGF21. Nature Reviews Endocrinology, 9(9), pp.506-508.
[16]. Duncan, B.B., Schmidt, M.I., Pankow, J.S., Bang, H., Couper, D., Ballantyne, C.M., Hoogeveen, R.C. and Heiss, G., 2004. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes, 53(9), pp.2473-2478.
[17]. Yadalam, P.K., Arumuganainar, D., Ronsivalle, V., Di Blasio, M., Badnjevic, A., Marrapodi, M.M., Cervino, G. and Minervini, G., 2024. Prediction of interactomic hub genes in PBMC cells in type 2 diabetes mellitus, dyslipidemia, and periodontitis. BMC Oral Health, 24(1), p.385.
[18]. Jiang, Y., Owei, I., Wan, J., Ebenibo, S. and Dagogo-Jack, S., 2016. Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. BMJ Open Diabetes Research and Care, 4(1), p.e000194.
[19]. Hushmandi, K., Einollahi, B., Aow, R., Suhairi, S.B., Klionsky, D.J., Aref, A.R., Reiter, R.J., Makvandi, P., Rabiee, N., Xu, Y. and Nabavi, N., 2024. Investigating the Interplay between Mitophagy and Diabetic Neuropathy: Uncovering the hidden secrets of the disease pathology. Pharmacological Research, p.107394.